Tango Therapeutics rises after leadership changes ahead of cancer drug data

Revolution Medicines

15/04/2026 14:57

** Shares of biotech firm Tango Therapeutics TNGX.O rise 3% to $24.65 in early trading

** Co says it appointed Matthew Gall as chief financial officer, replacing Daniella Beckman

** Gall previously served as CFO at Kalaris Therapeutics and iTeos Therapeutics, co says

** Co also names Yen‑Ching Chua as chief development operations officer to oversee clinical operations

** Janice Kapty appointed senior vice president for corporate strategy and project leadership, Co says

** Says leadership changes come as it advances vopimetostat, an experimental cancer drug, toward a key data readout

** Co says it expects to present initial data later this year from a combination trial with Revolution Medicines RVMD.O

** Including session's move, stock up about three fold YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))